Price Alert

Arcellx Inc. (ACLX)

NASDAQ: ACLX · Real-Time Price · USD

79.75

1.34 (1.72%)

At close: Sep 26, 2025, 3:59 PM

79.75

0.00%

After-hours: Sep 26, 2025, 04:28 PM EDT

1.72% (1D)

Bid	76.05
Market Cap	4.42B
Revenue (ttm)	56.98M
Net Income (ttm)	-187.99M
EPS (ttm)	-3.41
PE Ratio (ttm)	-23.39
Forward PE	-24.23
Analyst	Buy
Dividends	n/a

Ask	82
Volume	464,728
Avg. Volume (20D)	511,663
Open	78.96
Previous Close	78.41
Day's Range	77.54 - 80.42
52-Week Range	47.86 - 107.37
Beta	0.27
Ex-Dividend Date	n/a

About ACLX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ACLX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ACLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Arcellx Inc. is scheduled to release its earnings on Nov 6, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

10 months ago

+0.79%

Acrellx shares are trading lower after the company... Unlock content with Pro Subscription

News

2 weeks ago · seekingalpha.com

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christ...

3 weeks ago · businesswire.com

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...

1 month ago · seekingalpha.com

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

1 month ago · zacks.com

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago.

1 month ago · fool.com

Arcellx (ACLX) Q2 Revenue Drops 72%

2 months ago · seekingalpha.com

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data supp...